About

 Trevarx Biomedical discovers and develops novel radiopharmaceutical platforms that turn deadly diseases into manageable conditions. Our first radiopharmaceutical platform is a small molecule PARP inhibitor (PARPi) analogue that binds to the same NAD+ active site pocket of PARP-1 as do most approved therapeutic PARPi’s including olaparib, rucaparib, talazaparib and niraparib. Collectively, the PARPi market is projected to be $8 billion worldwide by 2027* and is currently approved in the US as treatment for patients with breast, prostate, ovarian, pancreatic cancers, and is in clinical trials for other cancer indications. Our first patented product, fluorine-18 Fluorthanatrace ([18F]FTT), measures tumor expression of PARP-1 and as such, is an accurate and safe PET biomarker for PARPi therapy. [18F]FTT will be entering Phase 2 multi-center trials with breast cancer patients in Spring 2022, led by MD Anderson Cancer Center with University of Pennsylvania and Washington University at St. Louis. Our second product, astatine-211 PTT ([211At]PTT), is an alpha-emitting radiotherapeutic which uses the same small molecule PARPi platform to deliver a cytotoxic radioactive payload directly to the PARP-1 tumor cell nucleus. Early studies have shown that [211At]PTT is over 1 billion times more cytotoxic to cancer cells than standard PARP’s. [211At]PTT is in the pre-clinical stage with plans for Phase 1 trials for a number of different disease indications, including neuroblastoma and glioblastoma.